| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00

LONDON—There is a merger and acquisition (M&A) opportunity for large contract manufacturing organizations (CMOs) in North America and Europe to acquire facilities able to produce medicines with lower operating expenses than in their own territories, says data and analytics company GlobalData—and that opportunity lies in Southeast Asia.

“Only 3 percent of CMO Indian facilities that sell solid dose drugs to North America, Europe and Japan are foreign-owned, and the majority of commercial solid dose facilities in India are owned by India-headquartered companies,” said Adam Bradbury, a PharmSource analyst at GlobalData. “Only six U.S., five U.K., and three German CMOs own solid dose manufacturing sites in India.

“While the Indian pharma industry is best known for its small-molecule active pharmaceutical ingredient (API) production—offered by almost half of the country’s contract manufacturing facilities—India also has a strong commercial dose and analytical services industry, often in the same facilities that manufacture APIs.”

Approximately 38 percent of Indian solid dose facilities have the regulatory approvals to supply the United States, Canada, the European Union and Japan.

Concluded Bradbury: “India’s presence among the top five countries shows the location’s appeal for contract manufacturers to supply developed markets; however, the facility count does not include all pharma facilities because many Indian CMOs only supply locally and do not have approvals to supply to the U.S., Europe or Japan, and many CMOs are headquartered in developed markets’ own local facilities.”

Related Topics

Published In

Volume 16 - Issue 10 | November 2020

November 2020

November 2020 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue